Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 308 results
Author [ Title(Asc)] Type Year
Filters: First Letter Of Last Name is B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Konnaris MA, Brendel M, Fontana MAlan, Otero M, Ivashkiv LB, Wang F, Bell RD.  2022.  Computational pathology for musculoskeletal conditions using machine learning: advances, trends, and challenges.. Arthritis Res Ther. 24(1):68.
Burke LG, Khullar D, Zheng J, Frakt AB, E Orav J, Jha AK.  2019.  Comparison of Costs of Care for Medicare Patients Hospitalized in Teaching and Nonteaching Hospitals.. JAMA Netw Open. 2(6):e195229.
Alexopoulos GS, Raue PJ, Banerjee S, Marino P, Renn BN, Solomonov N, Adeagbo A, Sirey JAnne, Hull TD, Kiosses DN et al..  2020.  Comparing the streamlined psychotherapy "Engage" with problem-solving therapy in late-life major depression. A randomized clinical trial.. Mol Psychiatry.
Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI, Hennessy S.  2014.  Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.. J Comp Eff Res. 3(1):29-39.
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, J Cairncross G, Wick W, Weller M et al..  2020.  CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.. Neuro Oncol.
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, J Cairncross G, Wick W, Weller M et al..  2020.  CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.. Neuro Oncol.
Magbanua MJesus M, Savenkov O, Asmus EJ, Ballman K, Scott JH, Park JW, Dickler M, Partridge AH, Carey LA, Winer E et al..  2020.  Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab.. Clin Cancer Res.
Tripathi S, Malhotra A, Qazi M, Chou J, Wang F, Barkan S, Hellmers N, Henchcliffe C, Sarva H.  2022.  Clinical Review of Smartphone Applications in Parkinson's Disease.. Neurologist. 27(4):183-193.
Columbo JA, Sedrakyan A, Mao J, Hoel AW, Trooboff SW, Kang R, Brown JR, Goodney PP.  2019.  Claims-based surveillance for reintervention after endovascular aneurysm repair among non-Medicare patients.. J Vasc Surg.
Rosenblatt R, Cohen-Mekelburg S, Shen N, Tafesh Z, Lucero C, Kumar S, Fortune B, Liu SYan, Brown R, Jesudian A.  2019.  Cirrhosis as a Comorbidity in Conditions Subject to the Hospital Readmissions Reduction Program.. Am J Gastroenterol. 114(9):1488-1495.
Al-Hajj S, Bcheraoui CEl, Daoud F, Khalil I, Moradi-Lakeh M, Abu-Raddad LJ, Hamadeh RR, Mokdad A.  2020.  Child and adolescent injury burden in the eastern mediterranean region: Findings from the Global Burden of Disease 1990-2017.. BMC Public Health. 20(1):433.
Prigerson HG, Bao Y, Shah MA, M Paulk E, LeBlanc TW, Schneider BJ, Garrido MM, M Reid C, Berlin DA, Adelson KB et al..  2015.  Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.. JAMA Oncol. 1(6):778-84.
Prigerson HG, Bao Y, Shah MA, M Paulk E, LeBlanc TW, Schneider BJ, Garrido MM, M Reid C, Berlin DA, Adelson KB et al..  2015.  Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.. JAMA Oncol. 1(6):778-84.
Garrido MM, Prigerson HG, Bao Y, Maciejewski PK.  2016.  Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life.. J Pain Symptom Manage. 51(5):875-881.e2.
Bao Y, Maciejewski RC, Garrido MM, Shah MA, Maciejewski PK, Prigerson HG.  2018.  Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.. J Pain Symptom Manage. 55(4):1113-1121.e3.
Linzer M, Poplau S, Prasad K, Khullar D, Brown R, Varkey A, Yale S, Grossman E, Williams E, Sinsky C.  2019.  Characteristics of Health Care Organizations Associated With Clinician Trust: Results From the Healthy Work Place Study.. JAMA Netw Open. 2(6):e196201.
Dinh CT, Linn KA, Isidro U, Emanuel EJ, Volpp KG, Bond AM, Caldarella K, Troxel AB, Zhu J, Yang L et al..  2020.  Changes in Outpatient Imaging Utilization and Spending Under a New Population-Based Primary Care Payment Model.. J Am Coll Radiol. 17(1 Pt B):101-109.
Dinh CT, Linn KA, Isidro U, Emanuel EJ, Volpp KG, Bond AM, Caldarella K, Troxel AB, Zhu J, Yang L et al..  2020.  Changes in Outpatient Imaging Utilization and Spending Under a New Population-Based Primary Care Payment Model.. J Am Coll Radiol. 17(1 Pt B):101-109.
Cannistra SA, Haffty BG, Ballman K.  2020.  Challenges Faced by Medical Journals During the COVID-19 Pandemic.. J Clin Oncol. :JCO2000858.
Bishop TF, Ramsay PP, Casalino LP, Bao Y, Pincus HA, Shortell SM.  2016.  Care Management Processes Used Less Often For Depression Than For Other Chronic Conditions In US Primary Care Practices.. Health Aff (Millwood). 35(3):394-400.
Bishop TF, Ramsay PP, Casalino LP, Bao Y, Pincus HA, Shortell SM.  2016.  Care Management Processes Used Less Often For Depression Than For Other Chronic Conditions In US Primary Care Practices.. Health Aff (Millwood). 35(3):394-400.
B
Benda NC, Veinot TC, Sieck CJ, Ancker JS.  2020.  Broadband Internet Access Is a Social Determinant of Health!. Am J Public Health. 110(8):1123-1125.
Su C, Hou Y, Zhou M, Rajendran S, Maasch JRMA, Abedi Z, Zhang H, Bai Z, Cuturrufo A, Guo W et al..  2023.  Biomedical discovery through the integrative biomedical knowledge hub (iBKH).. iScience. 26(4):106460.
Su C, Hou Y, Zhou M, Rajendran S, Maasch JRMA, Abedi Z, Zhang H, Bai Z, Cuturrufo A, Guo W et al..  2023.  Biomedical discovery through the integrative biomedical knowledge hub (iBKH).. iScience. 26(4):106460.
Khalil CAbi, Sulaiman K, Asaad N, AlHabib KF, Alsheikh-Ali A, Jameesh M, Al-Jarallah M, Bulbanat B, AlMahmeed W, Ridha M et al..  2019.  Beta-blockers and cardiovascular outcomes in acute heart failure with a history of coronary artery disease and an ejection fraction ≥ 40.. Curr Vasc Pharmacol.